Charles D Magee1, Stephen Witte2, Ryan M Kwok3, Patricia A Deuster4. 1. Department of Medicine, Division of Military Internal Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814. 2. Robinson Health Clinic, 1722 Tagayta Drive, Fort Bragg, NC 28310. 3. Department of Gastroenterology, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889. 4. Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.
Abstract
BACKGROUND: Supplement adulteration with anabolic-androgenic steroids (AAS) has been reported and AAS-associated drug-induced liver injury is clinically variable. OBJECTIVES: We present two cases of AAS-associated drug-induced liver injury in deployed service members, including the first report of clinical hepatotoxicity with desoxymethyltestosterone. We highlight variable hepatotoxicity patterns of AAS, raise concern with inaccurate supplement labeling and identify educational resources. METHODS: The first case presents with cholestatic jaundice following 10 weeks of prohormone use. Hepatobiliary imaging was unrevealing. Viral, autoimmune, and metabolic etiologies were excluded. Bilirubin normalized by 8 weeks after stopping the supplement. The second case presents with asymptomatic hepatocellular toxicity and marked dyslipidemia identified on service-related physical following 21 days of prohormone use. Aspartate aminotransferase and alanine aminotransferase normalized 4 weeks after supplement cessation; high-density lipoprotein and low-density lipoprotein returned to baseline at 8 weeks. Each supplement was volunteered for analytic testing. RESULTS: Supplement label contents did not match gas chromatography/mass spectrometry analysis; 3 of 4 supplements contained federally regulated AAS. CONCLUSIONS: AAS hepatotoxicity is clinically variable and dyslipidemia may be an important clinical indicator. False labeling introduces clinical risk and threatens mission readiness. Educational resources are available to facilitate information sharing. Supplement analysis informs of clinical risk of specific supplements and facilitates shared clinical decision-making. Reprint &
BACKGROUND: Supplement adulteration with anabolic-androgenic steroids (AAS) has been reported and AAS-associated drug-induced liver injury is clinically variable. OBJECTIVES: We present two cases of AAS-associated drug-induced liver injury in deployed service members, including the first report of clinical hepatotoxicity with desoxymethyltestosterone. We highlight variable hepatotoxicity patterns of AAS, raise concern with inaccurate supplement labeling and identify educational resources. METHODS: The first case presents with cholestatic jaundice following 10 weeks of prohormone use. Hepatobiliary imaging was unrevealing. Viral, autoimmune, and metabolic etiologies were excluded. Bilirubin normalized by 8 weeks after stopping the supplement. The second case presents with asymptomatic hepatocellular toxicity and marked dyslipidemia identified on service-related physical following 21 days of prohormone use. Aspartate aminotransferase and alanine aminotransferase normalized 4 weeks after supplement cessation; high-density lipoprotein and low-density lipoprotein returned to baseline at 8 weeks. Each supplement was volunteered for analytic testing. RESULTS: Supplement label contents did not match gas chromatography/mass spectrometry analysis; 3 of 4 supplements contained federally regulated AAS. CONCLUSIONS:AAS hepatotoxicity is clinically variable and dyslipidemia may be an important clinical indicator. False labeling introduces clinical risk and threatens mission readiness. Educational resources are available to facilitate information sharing. Supplement analysis informs of clinical risk of specific supplements and facilitates shared clinical decision-making. Reprint &
Authors: Ana Petrovic; Sonja Vukadin; Renata Sikora; Kristina Bojanic; Robert Smolic; Davor Plavec; George Y Wu; Martina Smolic Journal: World J Gastroenterol Date: 2022-07-14 Impact factor: 5.374
Authors: Robin Daniel Abeles; Matthew Foxton; Shahid Khan; Robert Goldin; Belinda Smith; Mark R Thursz; Suman Verma Journal: BMJ Open Gastroenterol Date: 2020-11